Rosmarinic acid suppresses colonic inflammation in dextran sulphate sodium (DSS)-induced mice via dual inhibition of NF-κB and STAT3 activation

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Jin, Bo Ram ^a   Chung, Kyung Sook ^b   Cheon, Se Yun ^a   Lee, Minho ^b   Hwang, Soonjae ^c   Noh Hwang, Sam ^c   Rhee, Ki Jong ^c   An, Hyo Jin ^a  

^a Sangji University   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Yonsei University Wonju   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AUTACOID; CINNAMIC ACID DERIVATIVE; CYCLOOXYGENASE 2; CYTOKINE; DEPSIDE; DEXTRAN SULFATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; PEROXIDASE; ROSMARINIC ACID; STAT3 PROTEIN;

ANIMAL; CHEMICALLY INDUCED; COLITIS; COLON; DISEASE EXACERBATION; DISEASE MODEL; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; INFLAMMATION; INSTITUTE FOR CANCER RESEARCH MOUSE; MALE; METABOLISM; PATHOLOGY; SPLEEN;

ANIMALS; CINNAMATES; COLITIS; COLON; CYCLOOXYGENASE 2; CYTOKINES; DEPSIDES; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION REGULATION; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; MICE, INBRED ICR; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; PEROXIDASE; SPLEEN; STAT3 TRANSCRIPTION FACTOR;

EID: 85017186965     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep46252     Document Type: Article

References (43)

1. Owczarek, D., Cibor, D., Szczepanek, M. & Mach, T. Biological therapy of inflammatory bowel disease. Polskie Archiwum Medycyny Wewnetrznej 119, 84-88 (2009).
2. Potack, J. & Itzkowitz, S. H. Colorectal cancer in inflammatory bowel disease. Gut and liver 2, 61-73, doi: 10.5009/gnl.2008.2.2.61 (2008).
3. Yu, H., Pardoll, D. & Jove, R. STATs in cancer inflammation and immunity: A leading role for STAT3. Nature reviews. Cancer 9, 798-809, doi: 10.1038/nrc2734 (2009).
4. Neurath, M. F. Cytokines in inflammatory bowel disease. Nature reviews. Immunology 14, 329-342, doi: 10.1038/nri3661 (2014).
5. Kolios, G., Valatas, V. & Ward, S. G. Nitric oxide in inflammatory bowel disease: A universal messenger in an unsolved puzzle. Immunology 113, 427-437, doi: 10.1111/j.1365-2567.2004.01984.x (2004).
6. Karin, M. & Ben-Neriah, Y. Phosphorylation meets ubiquitination: The control of NF-[kappa]B activity. Annual review of immunology 18, 621-663, doi: 10.1146/annurev.immunol.18.1.621 (2000).
7. Takeda, K., Kaisho, T. & Akira, S. Toll-like receptors. Annual review of immunology 21, 335-376, doi: 10.1146/annurev. immunol.21.120601.141126 (2003).
8. Uwe, S. Anti-inflammatory interventions of NF-kappaB signaling: potential applications and risks. Biochemical pharmacology 75, 1567-1579, doi: 10.1016/j.bcp.2007.10.027 (2008).
9. Aggarwal, B. B. et al. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship ? Annals of the New York Academy of Sciences 1171, 59-76, doi: 10.1111/j.1749-6632.2009.04911.x (2009).
10. Bromberg, J. & Wang, T. C. Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer cell 15, 79-80, doi: 10.1016/j. ccr.2009.01.009 (2009).
11. Zhao, M., Jiang, B. & Gao, F. H. Small molecule inhibitors of STAT3 for cancer therapy. Current medicinal chemistry 18, 4012-4018 (2011).
12. Suzuki, A. et al. CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. The Journal of experimental medicine 193, 471-481 (2001).
13. Amoah, S. K., Sandjo, L. P., Kratz, J. M. & Biavatti, M. W. Rosmarinic Acid-Pharmaceutical and Clinical Aspects. Planta medica 82, 388-406, doi: 10.1055/s-0035-1568274 (2016).
14. Oh, H. A., Park, C. S., Ahn, H. J., Park, Y. S. & Kim, H. M. Effect of Perilla frutescens var. acuta Kudo and rosmarinic acid on allergic inflammatory reactions. Experimental biology and medicine 236, 99-106, doi: 10.1258/ebm.2010.010252 (2011).
15. Jiang, W. L. et al. Rosmarinic acid protects against experimental sepsis by inhibiting proinflammatory factor release and ameliorating hemodynamics. Shock 32, 608-613, doi: 10.1097/SHK.0b013e3181a48e86 (2009).
16. Rocha, J. et al. Anti-inflammatory effect of rosmarinic acid and an extract of Rosmarinus officinalis in rat models of local and systemic inflammation. Basic & clinical pharmacology & toxicology 116, 398-413, doi: 10.1111/bcpt.12335 (2015).
17. Urushima, H. et al. Perilla frutescens extract ameliorates DSS-induced colitis by suppressing proinflammatory cytokines and inducing anti-inflammatory cytokines. American journal of physiology. Gastrointestinal and liver physiology 308, G32-41, doi: 10.1152/ajpgi.00294.2014 (2015).
18. Chassaing, B., Aitken, J. D., Malleshappa, M. & Vijay-Kumar, M. Dextran sulfate sodium (DSS)-induced colitis in mice. Current protocols in immunology/edited by John, E. Coligan [et al.] 104, Unit 15 25, doi: 10.1002/0471142735.im1525s104 (2014).
19. Kwon, K. H., Murakami, A., Hayashi, R. & Ohigashi, H. Interleukin-1beta targets interleukin-6 in progressing dextran sulfate sodium-induced experimental colitis. Biochemical and biophysical research communications 337, 647-654, doi: 10.1016/j. bbrc.2005.09.107 (2005).
20. Blennerhassett, M. G., Bovell, F. M., Lourenssen, S. & McHugh, K. M. Characteristics of inflammation-induced hypertrophy of rat intestinal smooth muscle cell. Digestive diseases and sciences 44, 1265-1272 (1999).
21. Zhang, J. M. & An, J. Cytokines, inflammation, and pain. International anesthesiology clinics 45, 27-37, doi: 10.1097/AIA.0b013e318034194e (2007).
22. Lerebours, E., Savoye, G. & Guedon, C. Epidemiology and natural history of chronic inflammatory bowel disease. Gastroenterologie clinique et biologique 27, S76-80 (2003).
23. Mulder, D. J., Noble, A. J., Justinich, C. J. & Duffin, J. M. A tale of two diseases: The history of inflammatory bowel disease. Journal of Crohns & colitis 8, 341-348, doi: 10.1016/j.crohns.2013.09.009 (2014).
24. Kaser, A., Zeissig, S. & Blumberg, R. S. Inflammatory bowel disease. Annual review of immunology 28, 573-621, doi: 10.1146/annurev-immunol-030409-101225 (2010).
25. Kao, J., Kwok, K. & Das, K. M. Inducing and maintaining remission in ulcerative colitis: role of high-dose, extended-release mesalamine. Journal of clinical gastroenterology 44, 531-535, doi: 10.1097/MCG.0b013e3181db1a61 (2010).
26. Cohen, H. D. & Das, K. M. The metabolism of mesalamine and its possible use in colonic diverticulitis as an anti-inflammatory agent. Journal of clinical gastroenterology 40 Suppl 3, S150-154, doi: 10.1097/01.mcg.0000212654.28527.d0 (2006).
27. Ke, F., Yadav, P. K. & Ju, L. Z. Herbal medicine in the treatment of ulcerative colitis. Saudi journal of gastroenterology: official journal of the Saudi Gastroenterology Association 18, 3-10, doi: 10.4103/1319-3767.91726 (2012).
28. Kim, G. D., Park, Y. S., Jin, Y. H. & Park, C. S. Production and applications of rosmarinic acid and structurally related compounds. Applied microbiology and biotechnology 99, 2083-2092, doi: 10.1007/s00253-015-6395-6 (2015).
29. Kiesler, P., Fuss, I. J. & Strober, W. Experimental Models of Inflammatory Bowel Diseases. Cellular and molecular gastroenterology and hepatology 1, 154-170, doi: 10.1016/j.jcmgh.2015.01.006 (2015).
30. Perse, M. & Cerar, A. Dextran sodium sulphate colitis mouse model: Traps and tricks. Journal of biomedicine & biotechnology 2012, 718617, doi: 10.1155/2012/718617 (2012).
31. Islam, M. S. et al. Anti-inflammatory effects of phytosteryl ferulates in colitis induced by dextran sulphate sodium in mice. British journal of pharmacology 154, 812-824, doi: 10.1038/bjp.2008.137 (2008).
32. Fujino, S. et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52, 65-70 (2003).
33. Cho, E. J. et al. Anti-inflammatory effects of methanol extract of Patrinia scabiosaefolia in mice with ulcerative colitis. Journal of ethnopharmacology 136, 428-435, doi: 10.1016/j.jep.2010.04.047 (2011).
34. Xiao, H. et al. The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis. Immunity 26, 461-475, doi: 10.1016/j.immuni.2007.02.012 (2007).
35. Baud, V. & Karin, M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nature reviews. Drug discovery 8, 33-40, doi: 10.1038/nrd2781 (2009).
36. Bharti, A. C., Donato, N., Singh, S. & Aggarwal, B. B. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 101, 1053-1062, doi: 10.1182/blood-2002-05-1320 (2003).
37. Hoesel, B. & Schmid, J. A. The complexity of NF-kappaB signaling in inflammation and cancer. Molecular cancer 12, 86, doi: 10.1186/1476-4598-12-86 (2013).
38. Hagihara, K. et al. Essential role of STAT3 in cytokine-driven NF-kappaB-mediated serum amyloid A gene expression. Genes to cells: devoted to molecular & cellular mechanisms 10, 1051-1063, doi: 10.1111/j.1365-2443.2005.00900.x (2005).
39. Lee, H. et al. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer cell 15, 283-293, doi: 10.1016/j.ccr.2009.02.015 (2009).
40. Dabritz, J., Judd, L. M., Chalinor, H. V., Menheniott, T. R. & Giraud, A. S. Altered gp130 signalling ameliorates experimental colitis via myeloid cell-specific STAT3 activation and myeloid-derived suppressor cells. Scientific reports 6, 20584, doi: 10.1038/srep20584 (2016).
41. Wen, Z., Zhong, Z. & Darnell, J. E. Jr. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 82, 241-250 (1995).
42. Decker, T. & Kovarik, P. Serine phosphorylation of STATs. Oncogene 19, 2628-2637, doi: 10.1038/sj.onc.1203481 (2000).
43. Rhee, K. J. et al. Induction of persistent colitis by a human commensal, enterotoxigenic Bacteroides fragilis, in wild-Type C57BL/6 mice. Infection and immunity 77, 1708-1718, doi: 10.1128/IAI.00814-08 (2009).